
Sol-Gel Technologies (SLGL) Stock Forecast & Price Target
Sol-Gel Technologies (SLGL) Analyst Ratings
Bulls say
Sol-Gel Technologies is poised to see significant financial success with the potential approval and launch of their top drug candidate, SGT-610, for the prevention of new basal cell carcinoma lesions in Gorlin syndrome patients. This drug, if approved, could generate over $270M in annual sales by 2035 and may lead to further opportunities for self-commercialization. Additionally, the completion of enrollment for SGT-610's pivotal Phase 3 trial and preparatory activities for a potential Phase 3 program in high-frequency BCC showcases the company's dedication to advancing their pipeline and expanding their market reach.
Bears say
Sol-Gel Technologies is facing a number of potential risks with their drug SGT-610, including the potential failure of their late-stage trial and inability to secure regulatory approval. Additionally, with a valuation of only $180M, the company's commercial and late-stage portfolio may not be enough to sustain long-term growth and stability. The upcoming top-line data release and potential FDA approval in late 2027 are crucial events for the future success of the company. Overall, there are significant challenges and uncertainties that may impact the company's financial and stock performance, leading to a negative outlook.
This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.
Sol-Gel Technologies (SLGL) Analyst Forecast & Price Prediction
Start investing in Sol-Gel Technologies (SLGL)
Order type
Buy in
Order amount
Est. shares
0 shares